Updated SUNMO phase 3 data show Mosun-Pola cuts progression risk by 62% vs R-GemOx, with a 75% ORR and 61% CR rate in second-line R/R LBCL at 28-month follow-up.
Elizabeth Budde, MD, PhD
Advertisement
Articles by Elizabeth Budde, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
How Often Do Health Insurers Deny Doctor-Recommended Care?
2
Acoramidis Shows Durable Benefit at 54 Months in ATTR-CM
3
Sudden Death in HFpEF Often Preceded by Clinical Decline
4
New Data Support Pimicotinib as Durable for Rare Tenosynovial Giant Cell Tumor
5